In clinical trials for lung cancer, the commonly candidate targeted antigens include human epidermal growth factor receptor 2 (HER2), inactive tyrosine-protein kinase TM receptor (ROR1), CD80/CD86, PD-L1, carcinoembryonic antigen (CEA), prostate stem cell antigen (PSCA), mucin 1 (MUC1), mesothelin (MSLN), and epidermal growth factor receptor (EGFR) (153). Here, MSLN is linked to lung carcinoma.